David Ricks, Eli Lilly CEO (Photographer: David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly hits the gas on tirzepatide in obe­si­ty, nabs rolling sub­mis­sion for po­ten­tial block­buster in­di­ca­tion

In the al­ready buzzy obe­si­ty drug mar­ket, Eli Lil­ly is the lat­est news­mak­er, nab­bing a fast-track des­ig­na­tion and rolling re­view from the FDA on Thurs­day.

While Lil­ly’s tirzepatide study in obe­si­ty ini­tial­ly read out pos­i­tive re­sults in April, it’s ini­ti­at­ing an FDA fil­ing as it awaits re­sults from a sec­ond Phase III study.

Lil­ly’s ini­tial SUR­MOUNT-1 study showed up to 22% weight loss, and as it not­ed to End­points News re­cent­ly, those re­sults are be­gin­ning to ap­proach lev­els of bariatric surgery which av­er­ages 25-30% of body weight loss.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.